Alfred Moss, MD
Adult Medicine · Gaffney, SCNPI 1245294107
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 767 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,589 and has fallen 60.8% since, to $1,405 in 2025.
Across 767 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- Amgen$1K
- Pfizer$1K
- Novo Nordisk$754
- Antares Pharma, Inc.$732
- plus $7K from 53 others
What the payments were for
- Food & beverage$14,278100%
- Education$660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolate$500
- VRAYLAR$348
- Nalocet$248
- TRELEGY ELLIPTA$248
- Symbravo$150
- Jornay PM 20mg capsules (Bottle of 100)$137
- Prolia$123
- Repatha$123
- NURTEC ODT$122
- FASENRA$122
- INJECTAFER$112
- AIMOVIG$101
- XIFAXAN$100
How this compares
Too few adult medicine providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 453 | $283,662 |
| FarxigaDapagliflozin Propanediol | 157 | $151,591 |
| OzempicSemaglutide | 127 | $150,738 |
| ProlateOxycodone Hcl/Acetaminophen | 33 | $109,221 |
| JardianceEmpagliflozin | 66 | $57,055 |
| VraylarCariprazine Hcl | 23 | $42,856 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $40,977 |
| EliquisApixaban | 42 | $36,195 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 946 | $33,751 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $32,145 |
| JanuviaSitagliptin Phosphate | 29 | $29,324 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 157 | $25,274 |
| LinzessLinaclotide | 27 | $23,376 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $20,186 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $18,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,981 | $186,961215 claims |
| Novo NordiskOzempic | $754 | $150,738127 claims |
| Forte Bio-pharma LLCProlate | $392 | $109,22133 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $613 | $66,964111 claims |
| AbbVieVraylar, Linzess | $1,708 | $66,23150 claims |
| Boehringer IngelheimJardiance | $232 | $57,05566 claims |
| MerckJanuvia, Janumet | $38 | $47,64551 claims |
| PfizerEliquis | $1,108 | $36,19542 claims |
| Lilly USA, LLCTrulicity | $668 | $15,51516 claims |
| Sanofi-aventis U.S. LLCLantus | $100 | $1,68913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other adult medicine in Gaffney
- Samuel OrrGaffney$157
- Katherine PeilSumter$8K
- Melanie MoleEasley$2K
- Jose Morales VazquezMyrtle Beach$2K
- Elaine Inman-WilliamsonAiken$2K
- Samai SupanOkatie$713
- Yvette-Marie PellegrinoBeaufort$635
- Kelly PassarelloSummerville$482
- Kelley MoodyHartsville$290
- Kelsey SeptimioFort Mill$229
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.